MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.

Scientific Reports 2018 July 6 [Link] Riedel T, Cavin S, van den Bergh H, Krueger T, Liaudet L, Ris HB, Dyson PJ, Perentes JY Abstract Human pleural mesothelioma is an incurable and chemoresistant cancer. Using a nude mouse xenograft model of human pleural mesothelioma, we show that RAPTA-T, a compound undergoing preclinical evaluation, enhances tumor […]

Comments Off on Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.

Peritoneal Metastases from Malignant Mesothelioma.

Surgical Oncology Clinics of North America 2018 July [Link] Li CY, Alexander HR Jr Abstract Diffuse malignant peritoneal mesothelioma (MPM) is a rare cancer that is ultimately fatal in almost all afflicted individuals. Morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. Patients with MPM most commonly […]

Comments Off on Peritoneal Metastases from Malignant Mesothelioma.

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.

British Journal of Cancer 2018 June 20 [Link] Xu D, Liang SQ, Yang H, Lüthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW Abstract BACKGROUND: Standard treatment for advanced malignant pleural mesothelioma (MPM) is a cisplatin/pemetrexed (MTA) regimen; however, this is confronted by drug resistance. Proteotoxic […]

Comments Off on Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.

Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity.

Oncotarget 2018 May 26 [Link] Chai K, Ning X, Nguyễn TTT, Zhong B, Morinaga T, Li Z, Shingyoji M, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Yamaguchi N, Tagawa M Abstract Heat shock protein 90 (HSP90) inhibitors suppressed MDM4 functions which mediated p53 ubiquitination, and blocked a chaperon function which influenced expression of the […]

Comments Off on Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity.

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Clinical Lung Cancer 2018 May 9 [Link] Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K

Comments Off on A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

Oncotarget 2018 April 27 [Link] Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a biologically highly aggressive tumor arising from the pleura with a […]

Comments Off on Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Journal of Thoracic Oncology 2018 May 3 [Link] Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ Abstract INTRODUCTION: The primary objective of this single-institution Phase I clinical trial was to establish the maximum tolerated dose (MTD) of gemcitabine added to cisplatin […]

Comments Off on A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Lung Cancer [Epub March 2018] [Link] Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C Abstract OBJECTIVES: Cisplatin-based chemotherapy is moderately active in malignant pleural mesothelioma (MPM) due to […]

Comments Off on Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo

Clinical cancer research 2018 May 3 [Link] Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirók A, Garay T, Stiglbauer A, Helbich TH, Groger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is an […]

Comments Off on Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo

Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

BMC Cancer 2018 April [Link] Wu L, Blum W, Zhu CQ, Yun Z, Pecze L, Kohno M, Chan ML, Zhao Y, Felley-Bosco E, Schwaller B, de Perrot M. Abstract BACKGROUND: Cancer cell repopulation during chemotherapy or radiotherapy is a major factor limiting the efficacy of treatment. Cancer stem cells (CSC) may play critical roles during […]

Comments Off on Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.